We hypothesize that scheduling QS RT to occur after three initial cycles of pembrolizumab will provide sufficient PD-L1 blockade at the time of QS to prompt the tumor immunogenicity incited by RT (Figure 1). The gene discussed is CD274; the disease is neoplasm.